375 related articles for article (PubMed ID: 1689355)
1. In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substituted side chain.
el-Zaatari FA; Sams KC; Taurog JD
J Immunol; 1990 Feb; 144(4):1512-7. PubMed ID: 1689355
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactive T cell clones from unrelated individuals reveal similarities in peptide presentation between HLA-B27 and HLA-DR2.
López D; Barber DF; Villadangos JA; López de Castro JA
J Immunol; 1993 Apr; 150(7):2675-86. PubMed ID: 7681078
[TBL] [Abstract][Full Text] [Related]
3. In vitro mutagenesis of HLA-B27. Substitution of an unpaired cysteine residue in the alpha 1 domain causes loss of antibody-defined epitopes.
Taurog JD; el-Zaatari FA
J Clin Invest; 1988 Sep; 82(3):987-92. PubMed ID: 2458390
[TBL] [Abstract][Full Text] [Related]
4. In vitro mutagenesis of HLA-B27: single and multiple amino acid substitutions at consensus B27 sites identify distinct monoclonal antibody-defined epitopes.
el-Zaatari FA; Taurog JD
Hum Immunol; 1992 Apr; 33(4):243-8. PubMed ID: 1379218
[TBL] [Abstract][Full Text] [Related]
5. A monoclonal antibody that recognizes HLA-B27 in the context of peptides.
Wang J; Yu DT; Fukazawa T; Kellner H; Wen J; Cheng XK; Roth G; Williams KM; Raybourne RB
J Immunol; 1994 Feb; 152(3):1197-205. PubMed ID: 8301124
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of human and mouse beta 2-microglobulin on the induction and the antigenic profile of endogenous HLA-A and -B antigens synthesized by beta 2-microglobulin gene-null FO-1 melanoma cells.
Wang Z; Hu XZ; Tatake RJ; Yang SY; Zeff RA; Ferrone S
Cancer Res; 1993 Sep; 53(18):4303-9. PubMed ID: 7689931
[TBL] [Abstract][Full Text] [Related]
7. Testing the importance of each residue in a HLA-B27-binding peptide using monoclonal antibodies.
Fukazawa T; Wang J; Huang F; Wen J; Tyan D; Williams KM; Raybourne RB; Yu DT
J Immunol; 1994 Feb; 152(3):1190-6. PubMed ID: 8301123
[TBL] [Abstract][Full Text] [Related]
8. A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2-specific antibodies and cytotoxic T lymphocytes.
Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
J Immunol; 1989 Mar; 142(6):2097-104. PubMed ID: 2466083
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule.
Santos-Aguado J; Barbosa JA; Biro PA; Strominger JL
J Immunol; 1988 Oct; 141(8):2811-8. PubMed ID: 2459229
[TBL] [Abstract][Full Text] [Related]
10. Role of binding pockets for amino-terminal peptide residues in HLA-B27 allorecognition.
Villadangos JA; Galocha B; López D; Calvo V; López de Castro JA
J Immunol; 1992 Jul; 149(2):505-10. PubMed ID: 1378067
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies against an HLA-B27-derived peptide react with an epitope present on bacterial proteins.
Raybourne RB; Williams KM
J Immunol; 1990 Oct; 145(8):2539-44. PubMed ID: 1698856
[TBL] [Abstract][Full Text] [Related]
12. Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3.
Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
J Immunol; 1988 Oct; 141(7):2519-25. PubMed ID: 2459215
[TBL] [Abstract][Full Text] [Related]
13. The effect of mutant beta 2-microglobulins on the conformation of HLA-B27 detected by antibody and by CTL.
Fukazawa T; Hermann E; Edidin M; Wen J; Huang F; Kellner H; Floege J; Farahmandian D; Williams KM; Yu DT
J Immunol; 1994 Oct; 153(8):3543-50. PubMed ID: 7930576
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain.
Tanabe M; Sekimata M; Ferrone S; Takiguchi M
J Immunol; 1992 May; 148(10):3202-9. PubMed ID: 1374450
[TBL] [Abstract][Full Text] [Related]
15. Association with beta 2-microglobulin controls the expression of transfected human class I genes.
Rein RS; Seemann GH; Neefjes JJ; Hochstenbach FM; Stam NJ; Ploegh HL
J Immunol; 1987 Feb; 138(4):1178-83. PubMed ID: 3543123
[TBL] [Abstract][Full Text] [Related]
16. Enhanced intracellular replication of Salmonella enteritidis in HLA-B27-expressing human monocytic cells: dependency on glutamic acid at position 45 in the B pocket of HLA-B27.
Penttinen MA; Heiskanen KM; Mohapatra R; DeLay ML; Colbert RA; Sistonen L; Granfors K
Arthritis Rheum; 2004 Jul; 50(7):2255-63. PubMed ID: 15248225
[TBL] [Abstract][Full Text] [Related]
17. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure.
Allen RL; O'Callaghan CA; McMichael AJ; Bowness P
J Immunol; 1999 May; 162(9):5045-8. PubMed ID: 10227970
[TBL] [Abstract][Full Text] [Related]
18. The amino acid at position 97 is involved in folding and surface expression of HLA-B27.
Blanco-Gelaz MA; Suárez-Alvarez B; González S; López-Vázquez A; Martínez-Borra J; López-Larrea C
Int Immunol; 2006 Jan; 18(1):211-20. PubMed ID: 16361312
[TBL] [Abstract][Full Text] [Related]
19. Overlapping peptide-binding specificities of HLA-B27 and B39: evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies.
Sobao Y; Tsuchiya N; Takiguchi M; Tokunaga K
Arthritis Rheum; 1999 Jan; 42(1):175-81. PubMed ID: 9920028
[TBL] [Abstract][Full Text] [Related]
20. Epitope mapping of HLA-B27 and HLA-B7 antigens by using intradomain recombinants.
Toubert A; Raffoux C; Boretto J; Sire J; Sodoyer R; Thurau SR; Amor B; Colombani J; Lemonnier FA; Jordan BR
J Immunol; 1988 Oct; 141(7):2503-9. PubMed ID: 2459214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
